CORNERSTONE PHARMACEUTICALS

Cornerstone Pharmaceuticals is committed to the development of therapies for rare cancers that have few to no treatment options available. Cornerstone's lead compound, CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth... Cornerstone Pharmaceuticals is developing innovative cancer therapies for the most intractable forms of the disease including AML, Burkitts pancreatic cancer.

Also known as: Cornerstone, Cornerstone Pharmaceuticals, Inc.

Primary location: Cranbury United States